Lipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen

Infection and Immunity

Volumn 81, Issue 7, 2013, Pages 2379-2393

  Leitner, Deborah R ^a   Feichter, Sandra ^a   Schild Prüfert, Kristina ^a   Rechberger, Gerald N ^a   Reidl, Joachim ^a   Schild, Stefan ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; DNA; LIPOPOLYSACCHARIDE; O ANTIGEN;

ARTICLE; BACTERIAL COLONIZATION; BACTERIAL OUTER MEMBRANE; CONTROLLED STUDY; DNA MODIFICATION; ENDOTOXICITY; IMMUNIZATION; MEMBRANE VESICLE; NONHUMAN; PRIORITY JOURNAL; TOXICITY; VIBRIO CHOLERAE;

ADHESINS, BACTERIAL; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; CHOLERA; CHOLERA VACCINES; FEMALE; FIMBRIAE PROTEINS; FLAGELLA; HUMANS; LIPID A; MACROPHAGES; MICE; MICE, INBRED BALB C; O ANTIGENS; TOXICITY TESTS; VIBRIO CHOLERAE;

EID: 84879430493     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01382-12     Document Type: Article

References (109)

1. Koch R. 1884. An address on cholera and its bacillus. Br. Med. J. 2:403-407.
2. Enserink M. 2010. Infectious diseases. Haiti's outbreak is latest in cholera's new global assault. Science 330:738-739.
3. CDC. 2010. Cholera outbreak-Haiti, October 2010. MMWR Morb. Mortal. Wkly. Rep. 59:1411.
4. Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB. 2012. Cholera. Lancet 379:2466-2476.
5. Sack DA, Sack RB, Nair GB, Siddique AK. 2004. Cholera. Lancet 363:223-233.
6. Levine MM. 2006. Enteric infections and the vaccines to counter them: future directions. Vaccine 24:3865-3873.
7. Bryce J, Boschi-Pinto C, Shibuya K, Black RE. 2005. WHO estimates of the causes of death in children. Lancet 365:1147-1152.
8. WHO. 2010. Cholera vaccines: WHO position paper. Wkly. Epidemiol. Rec. 85:117-128.
9. Zuckerman JN, Rombo L, Fisch A. 2007. The true burden and risk of cholera: implications for prevention and control. Lancet Infect. Dis. 7:521-530.
10. Kaper JB, Morris JG, Jr, Levine MM. 1995. Cholera. Clin. Microbiol. Rev. 8:48-86.
11. Clemens JD, Sack DA, Chakraborty J, Rao MR, Ahmed F, Harris JR, van Loon F, Khan MR, Yunis M, Huda S, Bradford AK, Svennerholm AM, Holmgren J. 1990. Field trial of oral cholera vaccines in Bangladesh: evaluation of anti-bacterial and anti-toxic breast-milk immunity in response to ingestion of the vaccines. Vaccine 8:469-472.
12. Jertborn M, Svennerholm AM, Holmgren J. 1992. Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 10:130-132.
13. Jertborn M, Svennerholm AM, Holmgren J. 1993. Evaluation of different immunization schedules for oral cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 11:1007-1012.
14. Jertborn M, Svennerholm AM, Holmgren J. 1994. Immunological memory after immunization with oral cholera B subunit-whole-cell vaccine in Swedish volunteers. Vaccine 12:1078-1082.
15. Bishop AL, Camilli A. 2011. Vibrio cholerae: lessons for mucosal vaccine design. Expert Rev. Vaccines 10:79-94.
16. Cumberland S. 2009. An old enemy returns. Bull. World Health Organ. 87:85-86.
17. Shin S, Desai SN, Sah BK, Clemens JD. 2011. Oral vaccines against cholera. Clin. Infect. Dis. 52:1343-1349.
18. Trach DD, Cam PD, Ke NT, Rao MR, Dinh D, Hang PV, Hung NV, Canh DG, Thiem VD, Naficy A, Ivanoff B, Svennerholm AM, Holmgren J, Clemens JD. 2002. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. Bull. World Health Organ. 80:2-8.
19. Desai SN, Clemens JD. 2012. An overview of cholera vaccines and their public health implications. Curr. Opin. Pediatr. 24:85-91.
20. Trach DD, Clemens JD, Ke NT, Thuy HT, Son ND, Canh DG, Hang PV, Rao MR. 1997. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 349:231-235.
21. Ryan ET, Calderwood SB, Qadri F. 2006. Live attenuated oral cholera vaccines. Expert Rev. Vaccines 5:483-494.
22. Asaduzzaman M, Ryan ET, John M, Hang L, Khan AI, Faruque AS, Taylor RK, Calderwood SB, Qadri F. 2004. The major subunit of the toxin-coregulated pilus TcpA induces mucosal and systemic immunoglobulin A immune responses in patients with cholera caused by Vibrio cholerae O1 and O139. Infect. Immun. 72:4448-4454.
23. Kossaczka Z, Shiloach J, Johnson V, Taylor DN, Finkelstein RA, Robbins JB, Szu SC. 2000. Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice. Infect. Immun. 68:5037-5043.
24. Cabrera O, Martinez ME, Cuello M, Soto CR, Valmaseda T, Cedre B, Gonzalez GS. 2006. Preparation and evaluation of Vibrio cholerae O1 EL Tor Ogawa lipopolysaccharide-tetanus toxoid conjugates. Vaccine 24(Suppl 2):S74 -S75.
25. Gupta RK, Szu SC, Finkelstein RA, Robbins JB. 1992. Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin. Infect. Immun. 60:3201-3208.
26. Garcia L, Jidy MD, Garcia H, Rodriguez BL, Fernandez R, Ano G, Cedre B, Valmaseda T, Suzarte E, Ramirez M, Pino Y, Campos J, Menendez J, Valera R, Gonzalez D, Gonzalez I, Perez O, Serrano T, Lastre M, Miralles F, Del Campo J, Maestre JL, Perez JL, Talavera A, Perez A, Marrero K, Ledon T, Fando R. 2005. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect. Immun. 73:3018-3024.
27. Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, Saha A, Alam MS, Zaman K, Seidlein LV, Park E, Killeen KP, Mekalanos JJ, Clemens JD, Sack DA. 2005. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J. Infect. Dis. 192:573-579.
28. Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, Saha A, Al Tarique A, Seidlein LV, Park E, Killeen KP, Mekalanos JJ, Clemens JD, Sack DA. 2007. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 25:231-238.
29. Tacket CO, Losonsky G, Nataro JP, Comstock L, Michalski J, Edelman R, Kaper JB, Levine MM. 1995. Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. J. Infect. Dis. 172:883-886.
30. Coster TS, Kileen KP, Waldor MK, Beattie D, Spriggs D, Kenner JR, Trofa A, Sadoff J, Mekalanos JJ, Taylor DN. 1995. Safety, immunogenicity and efficacy of a live attenuated Vibrio cholerae O139 vaccine prototype, Bengal-15. Lancet 345:949-952.
31. Bishop AL, Schild S, Patimalla B, Klein B, Camilli A. 2010. Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility. Infect. Immun. 78:4402-4420.
32. Schild S, Nelson EJ, Bishop AL, Camilli A. 2009. Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera. Infect. Immun. 77:472-484.
33. Schild S, Nelson EJ, Camilli A. 2008. Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. Infect. Immun. 76:4554-4563.
34. Mashburn-Warren L, McLean RJ, Whiteley M. 2008. Gram-negative outer membrane vesicles: beyond the cell surface. Geobiology 6:214- 219.
35. Kulp A, Kuehn MJ. 2010. Biological functions and biogenesis of secreted bacterial outer membrane vesicles. Annu. Rev. Microbiol. 64:163-184.
36. Chatterjee SN, Chaudhuri K. 2003. Lipopolysaccharides of Vibrio cholerae. I. Physical and chemical characterization. Biochim. Biophys. Acta 1639:65-79.
37. Follett EA, Gordon J. 1963. An electron microscope study of Vibrio flagella. J. Gen. Microbiol. 32:235-239.
38. Freter R, O'Brian PCM, Macsai MS. 1981. Role of chemotaxis in the association of motile bacteria with intestinal mucosa: in vivo studies. Infect. Immun. 34:234-240.
39. Freter R, Jones GW. 1976. Adhesive properties of Vibrio cholerae: nature of the interaction with intact mucosal surfaces. Infect. Immun. 14:246- 256.
40. Lee SH, Butler SM, Camilli A. 2001. Selection for in vivo regulators of bacterial virulence. Proc. Natl. Acad. Sci. U. S. A. 98:6889-6894.
41. Liu Z, Miyashiro T, Tsou A, Hsiao A, Goulian M, Zhu J. 2008. Mucosal penetration primes Vibrio cholerae for host colonization by repressing quorum sensing. Proc. Natl. Acad. Sci. U. S. A. 105:9769-9774.
42. Morris DC, Peng F, Barker JR, Klose KE. 2008. Lipidation of an FlrC-dependent protein is required for enhanced intestinal colonization by Vibrio cholerae. J. Bacteriol. 190:231-239.
43. Raetz CR, Whitfield C. 2002. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71:635-700.
44. Mukaida N, Ishikawa Y, Ikeda N, Fujioka N, Watanabe S, Kuno K, Matsushima K. 1996. Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cell-free system targeting NF-kappaB and regulation of cytokine production/ action through beta2 integrin in vivo. J. Leukoc. Biol. 59:145-151.
45. Engelhardt R, Mackensen A, Galanos C, Andreesen R. 1990. Biological response to intravenously administered endotoxin in patients with advanced cancer. J. Biol. Response Mod. 9:480-491.
46. Inagawa H, Kohchi C, Soma G. 2011. Oral administration of lipopolysaccharides for the prevention of various diseases: benefit and usefulness. Anticancer Res. 31:2431-2436.
47. Cross AS, Opal SM, Palardy JE, Drabick JJ, Warren HS, Huber C, Cook P, Bhattacharjee AK. 2003. Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. Vaccine 21: 4576-4587.
48. Rioux S, Girard C, Dubreuil JD, Jacques M. 1998. Evaluation of the protective efficacy of Actinobacillus pleuropneumoniae serotype 1 detoxified lipopolysaccharides or O-polysaccharide-protein conjugate in pigs. Res. Vet. Sci. 65:165-167.
49. Bhattacharjee AK, Opal SM, Taylor R, Naso R, Semenuk M, Zollinger WD, Moran EE, Young L, Hammack C, Sadoff JC, Cross AS. 1996. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis group B outer membrane protein produces protective antibodies against gramnegative bacteremia. J. Infect. Dis. 173:1157-1163.
50. Konadu E, Shiloach J, Bryla DA, Robbins JB, Szu SC. 1996. Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls. Infect. Immun. 64:2709-2715.
51. Ding HF, Nakoneczna I, Hsu HS. 1990. Protective immunity induced in mice by detoxified Salmonella lipopolysaccharide. J. Med. Microbiol. 31:95-102.
52. Sadarangani M, Pollard AJ. 2010. Serogroup B meningococcal vaccines- an unfinished story. Lancet Infect. Dis. 10:112-124.
53. Holst J, Martin D, Arnold R, Huergo CC, Oster P, O'Hallahan J, Rosenqvist E. 2009. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27(Suppl 2):B3-B12.
54. Van der Ley P, van den Dobbelsteen G. 2011. Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants. Hum. Vaccin. 7:886-890.
55. Keiser PB, Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto VB, Burden RE, Miller LB, Moon JE, Bowden RA, Cummings JF, Zollinger WD. 2011. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factorHbinding protein, two PorAs and stabilized OpcA expression. Vaccine 29:1413-1420.
56. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. 2005. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23:2191-2196.
57. Fredriksen JH, Rosenqvist E, Wedege E, Bryn K, Bjune G, Froholm LO, Lindbak AK, Mogster B, Namork E, Rye U, Stabbetorp G, Winsnes R, Aase B, Closs O. 1991. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 14:67-79, discussion 79-80.
58. Iwanaga M, Yamamoto K. 1985. New medium for the production of cholera toxin by Vibrio cholerae O1 biotype El Tor. J. Clin. Microbiol. 22:405-408.
59. Iwanaga M, Yamamoto K, Higa N, Ichinose Y, Nakasone N, Tanabe M. 1986. Culture conditions for stimulating cholera toxin production by Vibrio cholerae O1 El Tor. Microbiol. Immunol. 30:1075-1083.
60. Seper A, Fengler VH, Roier S, Wolinski H, Kohlwein SD, Bishop AL, Camilli A, Reidl J, Schild S. 2011. Extracellular nucleases and extracellular DNA play important roles in Vibrio cholerae biofilm formation. Mol. Microbiol. 82:1015-1037.
61. Donnenberg MS, Kaper JB. 1991. Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector. Infect. Immun. 59:4310-4317.
62. Tsai CM, Frasch CE. 1982. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal. Biochem. 119:115-119.
63. Lee CH, Tsai CM. 1999. Quantification of bacterial lipopolysaccharides by the Purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation. Anal. Biochem. 267:161-168.
64. Shevchenko A, Wilm M, Vorm O, Mann M. 1996. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68:850-858.
65. Folch J, Lees M, Sloane Stanley GH. 1957. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226:497-509.
66. Harrison LM, Rallabhandi P, Michalski J, Zhou X, Steyert SR, Vogel SN, Kaper JB. 2008. Vibrio cholerae flagellins induce Toll-like receptor 5-mediated interleukin-8 production through mitogen-activated protein kinase and NF-kappaB activation. Infect. Immun. 76:5524-5534.
67. Taylor RK, Kirn TJ, Meeks MD, Wade TK, Wade WF. 2004. A Vibrio cholerae classical TcpA amino acid sequence induces protective antibody that binds an area hypothesized to be important for toxin-coregulated pilus structure. Infect. Immun. 72:6050-6060.
68. Kang D, Gho YS, Suh M, Kang C. 2002. Highly sensitive and fast protein detection with coomassie brilliant blue in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Bull. Kor. Chem. Soc. 23:1511- 1512.
69. Roier S, Leitner DR, Iwashkiw J, Schild-Prufert K, Feldman MF, Krohne G, Reidl J, Schild S. 2012. Intranasal immunization with nontypeable Haemophilus influenzae outer membrane vesicles induces crossprotective immunity in mice. PLoS One 7:e42664. doi:10.1371/journal.pone.0042664.
70. Hankins JV, Madsen JA, Giles DK, Childers BM, Klose KE, Brodbelt JS, Trent MS. 2011. Elucidation of a novel Vibrio cholerae lipid A secondary hydroxy-acyltransferase and its role in innate immune recognition. Mol. Microbiol. 81:1313-1329.
71. Matson JS, Yoo HJ, Hakansson K, Dirita VJ. 2010. Polymyxin B resistance in El Tor Vibrio cholerae requires lipid acylation catalyzed by MsbB. J. Bacteriol. 192:2044-2052.
72. Somerville JE, Jr, Cassiano L, Bainbridge B, Cunningham MD, Darveau RP. 1996. A novel Escherichia coli lipid A mutant that produces an antiinflammatory lipopolysaccharide. J. Clin. Invest. 97:359-365.
73. Ranallo RT, Kaminski RW, George T, Kordis AA, Chen Q, Szabo K, Venkatesan MM. 2012. Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants. Infect. Immun. 78:400-412.
74. Teghanemt A, Zhang D, Levis EN, Weiss JP, Gioannini TL. 2005. Molecular basis of reduced potency of underacylated endotoxins. J. Immunol. 175:4669-4676.
75. Hankins JV, Madsen JA, Giles DK, Brodbelt JS, Trent MS. 2012. Amino acid addition to Vibrio cholerae LPS establishes a link between surface remodeling in gram-positive and gram-negative bacteria. Proc. Natl. Acad. Sci. U. S. A. 109:8722-8727.
76. Nesper J, Schild S, Lauriano CM, Kraiss A, Klose KE, Reidl J. 2002. Role of Vibrio cholerae O139 surface polysaccharides in intestinal colonization. Infect. Immun. 70:5990-5996.
77. Marolda CL, Vicarioli J, Valvano MA. 2004. Wzx proteins involved in biosynthesis of O antigen function in association with the first sugar of the O-specific lipopolysaccharide subunit. Microbiology 150:4095- 4105.
78. Feldman MF, Marolda CL, Monteiro MA, Perry MB, Parodi AJ, Valvano MA. 1999. The activity of a putative polyisoprenol-linked sugar translocase (Wzx) involved in Escherichia coli O antigen assembly is independent of the chemical structure of the O repeat. J. Biol. Chem. 274: 35129-35138.
79. Schild S, Lamprecht AK, Reidl J. 2005. Molecular and functional characterization of O antigen transfer in Vibrio cholerae. J. Biol. Chem. 280: 25936-25947.
80. Sharma DP, Stroeher UH, Thomas CJ, Manning PA, Attridge SR. 1989. The toxin-coregulated pilus (TCP) of Vibrio cholerae: molecular cloning of genes involved in pilus biosynthesis and evaluation of TCP as a protective antigen in the infant mouse model. Microb. Pathog. 7:437- 448.
81. Taylor RK, Kirn TJ, Bose N, Stonehouse E, Tripathi SA, Kovac P, Wade WF. 2004. Progress towards development of a cholera subunit vaccine. Chem. Biodivers. 1:1036-1057.
82. Hone DM, Powell J, Crowley RW, Maneval D, Lewis GK. 1998. Lipopolysaccharide from an Escherichia coli htrB msbB mutant induces high levels of MIP-1 alpha and MIP-1 beta secretion without inducing TNF-alpha and IL-1 beta. J. Hum. Virol. 1:251-256.
83. Kim SH, Kim KS, Lee SR, Kim E, Kim MS, Lee EY, Gho YS, Kim JW, Bishop RE, Chang KT. 2009. Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles. Biochim. Biophys. Acta 1788:2150-2159.
84. Fisseha M, Chen P, Brandt B, Kijek T, Moran E, Zollinger W. 2005. Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect. Immun. 73:4070-4080.
85. Van der Ley P, Steeghs L, Hamstra HJ, ten Hove J, Zomer B, van Alphen L. 2001. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect. Immun. 69:5981-5990.
86. Pridmore AC, Wyllie DH, Abdillahi F, Steeghs L, van der Ley P, Dower SK, Read RC. 2001. A lipopolysaccharide-deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via toll-like receptor (TLR) 2 but not via TLR4/ MD2. J. Infect. Dis. 183:89-96.
87. Gaines Das RE, Brugger P, Patel M, Mistry Y, Poole S. 2004. Monocyte activation test for pro-inflammatory and pyrogenic contaminants of parenteral drugs: test design and data analysis. J. Immunol. Methods 288: 165-177.
88. Voss E, Manning PA, Attridge SR. 1996. The toxin-coregulated pilus is a colonization factor and protective antigen of Vibrio cholerae El Tor. Microb. Pathog. 20:141-153.
89. Sun DX, Mekalanos JJ, Taylor RK. 1990. Antibodies directed against the toxin-coregulated pilus isolated from Vibrio cholerae provide protection in the infant mouse experimental cholera model. J. Infect. Dis. 161: 1231-1236.
90. Sharma DP, Thomas C, Hall RH, Levine MM, Attridge SR. 1989. Significance of toxin-coregulated pili as protective antigens of Vibrio cholerae in the infant mouse model. Vaccine 7:451-456.
91. Albert MJ, Alam K, Ansaruzzaman M, Qadri F, Sack RB. 1994. Lack of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR. J. Infect. Dis. 169:230-231.
92. Albert MJ, Alam K, Rahman AS, Huda S, Sack RB. 1994. Lack of cross-protection against diarrhea due to Vibrio cholerae O1 after oral immunization of rabbits with V. cholerae O139 Bengal. J. Infect. Dis. 169:709-710.
93. Svennerholm AM. 1975. Experimental studies on cholera immunization. The antibody response to formalinized Vibrio cholerae and purified endotoxin with special reference to protective capacity. Int. Arch. Allergy Appl. Immunol. 49:434-452.
94. Svennerholm AM, Holmgren J. 1976. Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid. Infect. Immun. 13:735-740.
95. Provenzano D, Kovac P, Wade WF. 2006. The ABCs (Antibody, B cells, and Carbohydrate epitopes) of cholera immunity: considerations for an improved vaccine. Microbiol. Immunol. 50:899-927.
96. Mukhopadhyay S, Nandi B, Ghose AC. 2000. Antibodies (IgG) to lipopolysaccharide of Vibrio cholerae O1 mediate protection through inhibition of intestinal adherence and colonisation in a mouse model. FEMS Microbiol. Lett. 185:29-35.
97. Vijayashree S, Nayak N, Panigrahi D, Sehgal S. 2003. Role of cell surface antigens of Vibrio cholerae 01 and non 01 serovars in intestinal adhesion. Indian J. Pathol. Microbiol. 46:259-260.
98. Johnson RA, Uddin T, Aktar A, Mohasin M, Alam MM, Chowdhury F, Harris JB, Larocque RC, Kelly Bufano M, Yu Y, Wu-Freeman Y, Leung DT, Sarracino D, Krastins B, Charles RC, Xu P, Kovac P, Calderwood SB, Qadri F, Ryan ET. 2012. Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera. Clin. Vaccine Immunol. 19:1712-1721.
99. Patel SM, Rahman MA, Mohasin M, Riyadh MA, Leung DT, Alam MM, Chowdhury F, Khan AI, Weil AA, Aktar A, Nazim M, LaRocque RC, Ryan ET, Calderwood SB, Qadri F, Harris JB. 2012. Memory B cell responses to Vibrio cholerae O1 lipopolysaccharide are associated with protection against infection from household contacts of patients with cholera in Bangladesh. Clin. Vaccine Immunol. 19:842-848.
100. Stein KE. 1992. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J. Infect. Dis. 165(Suppl 1):S49 -S52.
101. Orr N, Robin G, Cohen D, Arnon R, Lowell GH. 1993. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect. Immun. 61:2390-2395.
102. Mann JF, Acevedo R, Campo JD, Perez O, Ferro VA. 2009. Delivery systems: A vaccine strategy for overcoming mucosal tolerance? Expert Rev. Vaccines 8:103-112.
103. Hanahan D. 1983. Studies on transformation of Escherichia coli with plasmids. J. Mol. Biol. 166:557-580.
104. Miller VL, Mekalanos JJ. 1988. A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in Vibrio cholerae requires toxR. J. Bacteriol. 170:2575-2583.
105. Bishop AL, Tarique AA, Patimalla B, Calderwood SB, Qadri F, Camilli A. 2012. Immunization of mice with Vibrio cholerae outer-membrane vesicles protects against hyperinfectious challenge and blocks transmission. J. Infect. Dis. 205:412-421.
106. Miller VL, DiRita VJ, Mekalanos JJ. 1989. Identification of toxS, a regulatory gene whose product enhances toxR-mediated activation of the cholera toxin promoter. J. Bacteriol. 171:1288-1293.
107. Waldor MK, Mekalanos JJ. 1994. Emergence of a new cholera pandemic: molecular analysis of virulence determinants in Vibrio cholerae O139 and development of a live vaccine prototype. J. Infect. Dis. 170: 278-283.
108. Guzman L-M, Beblin D, Carson MJ, Beckwith J. 1995. Tight regulation, modulation, and high-level expression by vectors containing the arabinose pBAD promotor. J. Bacteriol. 177:4121-4130.
109. Nesper J, Kraiss A, Schild S, Blass J, Klose KE, Bockemuhl J, Reidl J. 2002. Comparative and genetic analyses of the putative Vibrio cholerae lipopolysaccharide core oligosaccharide biosynthesis (wav) gene cluster. Infect. Immun. 70:2419-2433.